NASDAQ:CTXR

Citius Pharmaceuticals - CTXR Stock Forecast, Price & News

$0.98

-0.04 (-3.94%)

(As of 03/20/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.96
▼
$1.03
50-Day Range: $0.92
▼
$1.42
52-Week Range: $0.77
▼
$2.01

Volume: 675,985 shs
Average Volume: 882,003 shs
Market Capitalization: $142.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

About Citius Pharmaceuticals (NASDAQ:CTXR) Stock

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Receive CTXR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CTXR Stock News Headlines

March 18, 2023 | uk.finance.yahoo.com

Citius Pharmaceuticals, Inc. (CTXR)

March 8, 2023 | finance.yahoo.com

Citius Pharmaceuticals to Participate in the 35th Annual Roth Conference

March 21, 2023 | Investing Daily (Ad)

This Trade Strategy Outpaces Almost Anything

Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself.

February 10, 2023 | finance.yahoo.com

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update

February 6, 2023 | finance.yahoo.com

Here Are 2 Ways I'm Playing the Market With Small-Cap Stocks

January 16, 2023 | finance.yahoo.com

Here's Why We're Not Too Worried About Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

January 11, 2023 | finance.yahoo.com

Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023

December 28, 2022 | finance.yahoo.com

After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR)

March 21, 2023 | Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

December 22, 2022 | benzinga.com

Citius Pharmaceuticals Reports $41.7M In Cash And Cash Equivalents As Of Sept. 30

December 22, 2022 | finance.yahoo.com

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update

December 1, 2022 | nasdaq.com

Citius: FDA To Review BLA For Denileukin Diftitox - Quick Facts

December 1, 2022 | finance.yahoo.com

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

November 21, 2022 | finance.yahoo.com

Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program

November 9, 2022 | finance.yahoo.com

Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (ASH) Annual Meeting

October 18, 2022 | finance.yahoo.com

Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Profit Outlook

October 18, 2022 | finance.yahoo.com

Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022

October 6, 2022 | finance.yahoo.com

Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022

September 28, 2022 | nasdaq.com

Citius Pharma Announces BLA Filing For Denileukin Diftitox - Quick Facts

September 28, 2022 | marketwatch.com

Citius Pharmaceuticals Seeks FDA OK of Reformulated Ontak Drug >CTXR

September 28, 2022 | finance.yahoo.com

Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

September 23, 2022 | seekingalpha.com

Citius gains on clinical collaboration to study cancer candidate

September 23, 2022 | finance.yahoo.com

Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Metastatic Solid Cancer Tumors in a Phase 1 Investigator-Initiated Trial

September 10, 2022 | benzinga.com

Citius Pharmaceuticals, Inc. to Present at the H....

September 7, 2022 | finance.yahoo.com

Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 11, 2022 | finance.yahoo.com

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update

August 9, 2022 | finance.yahoo.com

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CTXR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CTXR Company Calendar

Last Earnings: 12/22/2022
Today: 3/20/2023
Next Earnings (Estimated): 5/11/2023
Fiscal Year End: 9/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CTXR
CUSIP: N/A
CIK: 1506251
Web: www.citiuspharma.com
Phone: (908) 967-6677
Fax: N/A
Employees: 15
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.18)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,640,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -29.19%
Return on Assets: -26.67%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.33
Quick Ratio: 9.33

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.71 per share
Price / Book: 1.37

Miscellaneous

Outstanding Shares: 146,260,000
Free Float: 123,442,000
Market Cap: $142.72 million
Optionable: Not Optionable
Beta: 1.40

Key Executives

Leonard L. Mazur
Chairman, Chief Executive Officer & Secretary

Gary F. Talarico
Executive Vice President-Operations

Jaime Bartushak
Chief Financial & Business Officer

Alan Lader
SVP, Head-Clinical Operations & Quality Assurance

Myron S. Czuczman
Chief Medical Officer & Executive Vice President

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CTXR Stock - Frequently Asked Questions

How have CTXR shares performed in 2023?: Citius Pharmaceuticals' stock was trading at $0.79 on January 1st, 2023. Since then, CTXR stock has increased by 23.5% and is now trading at $0.9758.
View the best growth stocks for 2023 here.
When is Citius Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our CTXR earnings forecast.
How were Citius Pharmaceuticals' earnings last quarter?: Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) posted its earnings results on Thursday, December, 22nd. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.01.
When did Citius Pharmaceuticals' stock split?: Shares of Citius Pharmaceuticals reverse split on the morning of Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 8th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Citius Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Citius Pharmaceuticals investors own include Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL), KushCo (KSHB) and Gran Tierra Energy (GTE).

What is Citius Pharmaceuticals' stock symbol?: Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR."
Who are Citius Pharmaceuticals' major shareholders?: Citius Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.91%), Millennium Management LLC (0.38%), GSA Capital Partners LLP (0.34%), Renaissance Technologies LLC (0.28%), HighTower Advisors LLC (0.13%) and Morgan Stanley (0.08%).
View institutional ownership trends.
How do I buy shares of Citius Pharmaceuticals?: Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Citius Pharmaceuticals' stock price today?: One share of CTXR stock can currently be purchased for approximately $0.98.
How much money does Citius Pharmaceuticals make?: Citius Pharmaceuticals (NASDAQ:CTXR) has a market capitalization of $142.72 million. The company earns $-33,640,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis.
How can I contact Citius Pharmaceuticals?: Citius Pharmaceuticals' mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The official website for the company is www.citiuspharma.com. The company can be reached via phone at (908) 967-6677 or via email at ir@citiuspharma.com.

This page (NASDAQ:CTXR) was last updated on 3/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Citius Pharmaceuticals - CTXR Stock Forecast, Price & News

About Citius Pharmaceuticals (NASDAQ:CTXR) Stock

CTXR Stock News Headlines

CTXR Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

CTXR Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info